GGrantIndex
Sort

48,018 grants matching immunotherapy

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

$2,801,829
Judith S. Currier · University Of California Los Angeles · UM1 · FY2024 · AI

Targetable epigenetic and transcriptional mechanisms in melanoma thatshape the microenvironment

$2,800,993
David E Fisher · Massachusetts General Hospital · P01 · FY2024 · CA

SPORE in Skin Cancer

$2,800,906
Brigham And Women'S Hospital · P50 · FY2002 · CA

ETIB Clinical Research Core

$2,789,851
Ronald Gress · Division Of Basic Sciences - Nci · ZID · FY2018 · CA

THERAPY OF CML

$2,789,679
University Of Texas Md Anderson Can Ctr · P01 · FY2002 · CA

Cytokine signaling, immunoregulation and autoimmune disease

$2,782,678
John O'Shea · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2021 · AR

Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19

$2,782,255
Carl H. June · University Of Pennsylvania · P01 · FY2023 · CA

Vaccine Induced Immunity in the Young and Aged

$2,782,096
Rafi Ahmed · Emory University · U19 · FY2021 · AI

Pediatric Brain Tumor Consortium (PBTC)

$2,781,436
Arzu Onar-Thomas · St. Jude Children'S Research Hospital · UM1 · FY2019 · CA

Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections

$2,779,955
Mariette Barbier · West Virginia University · R01 · FY2025 · AI

Detection, prevention and treatment of acute myeloid leukemia (AML) relapse.

$2,779,530
Christopher Hourigan · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL

Synergies among inhibitory receptors in tolerance and disease

$2,775,439
Dario Aa Vignali · University Of Pittsburgh At Pittsburgh · P01 · FY2025 · AI

Statistics Core for SWOG SDMC

$2,771,034
Michael Leo Leblanc · Fred Hutchinson Cancer Center · U10 · FY2024 · CA

Bone Marrow Transplantation in Human Disease

$2,770,981
Johns Hopkins University · P01 · FY2005 · CA

Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders

$2,767,364
Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2014 · HL

Comprehensive Cancer Center Program at Fox Chase

$2,763,834
Richard I Fisher · Research Inst Of Fox Chase Can Ctr · P30 · FY2017 · CA

Interleukin-15 Production for Treatment of Patients with Metastatic Malignancy

$2,760,232
Thomas Waldmann · Division Of Basic Sciences - Nci · ZIB · FY2019 · CA

Enhancing Chimeric Antigen Receptor T Cell Therapies for Hematologic Malignancies: Beyond CART 19

$2,756,111
Carl H. June · University Of Pennsylvania · P01 · FY2019 · CA

Genetic, Cellular and Molecular Mechanisms in Autoimmunity to Retina

$2,755,137
Rachel R. Caspi · National Eye Institute · ZIA · FY2016 · EY

Statistics Core for SWOG SDMC

$2,750,305
Michael Leo Leblanc · Fred Hutchinson Cancer Research Center · U10 · FY2020 · CA

Consolidated Basic Cancer Research Program

$2,749,311
Dario C. Altieri · Wistar Institute · P30 · FY2019 · CA

The Biology of HIV Infections

$2,748,797
Malcolm Martin · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI

Interleukin-15 Production for Treatment of Patients with Metastatic Malignancy

$2,747,943
Thomas Waldmann · Division Of Basic Sciences - Nci · ZIB · FY2018 · CA

The Role of Inflammasome Signaling in Tauopathies

$2,745,818
Kiran Bhaskar · University Of New Mexico Health Scis Ctr · RF1 · FY2020 · NS

Bone Marrow Transplantation in Human Disease

$2,743,438
Johns Hopkins University · P01 · FY2002 · CA